This is a working overview of Stenabolic, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Isoforms == Different isoforms of retinal dehydrogenase exist and play a key role in development, as the types are differentially expressed inside a developing embryo. The enzyme retinal dehydrogenase type-2 (ALDH1A2 or RALDH2) catalyzes much of the retinoic acid formation during development, but not all. ALDH1A2 is crucial for development midgestation and helps drive neural, heart, lung, and forelimb development; it is also responsible for all retinoic acid development during certain periods of midgestation. Later in development, retinal dehydrogenase type-1 (ALDH1A1 or RALDH1) begins activity in the dorsal pit of the retina and retinal dehydrogenase type-3 (ALDH1A3 or RALDH3) becomes active in the olfactory pit, ventral retina, and urinary tract. ALDH1A2 gene knockouts are fatal in mice during development since the brain cannot develop normally. ALDH1A3 gene knockout is fatal at birth in mice since nasal passages are not properly developed and instead are blocked. ALDH1A1 knockouts are not fatal and, interestingly, have been shown to be protective against diet-induced obesity in mice in a retinoid-independent manner.
== Nomenclature == In 1997, Jamie I. Fletcher and his research associates introduced new nomenclature for classifying Australian funnel web spider toxins. They suggested replacing the trivial name 'versutoxin' with delta-hexatoxin-Hv1 instead. The delta represents the main biological activity of the neurotoxin; inhibiting sodium channels. In more recent research, atracotoxins have been rebranded as hexatoxins, but the two are still used interchangeably along with the abbreviations HXTX and ACTX. Delta and Hv1 are still used to specify the neurotoxic peptide versutoxin.
== Taxonomy == The American kestrel was formally described in 1758 by the Swedish naturalist Carl Linnaeus in the tenth edition of his Systema Naturae under the current binomial name Falco sparverius. Linnaeus based his account on the "little hawk" that had been described and illustrated by the English naturalist Mark Catesby in his book The Natural History of Carolina, Florida and the Bahama Islands that was published between 1729 and 1732. Linnaeus specified the type locality as America but this was restricted to South Carolina based on Catesby. Based on appearance and behavior it was for many years considered a member of the primarily European and African kestrel clade within the genus Falco, but DNA analysis shows the American kestrel is instead genetically more closely related to all other falcons, placed basal to all of the "non-kestrel" falcons. Though the species is thus not actually a kestrel in the phylogenetic sense, it has not been renamed as a result of these genetic analyses. A process of convergent evolution to fit a similar ecosystem niche, hunting small, largely ground-dwelling, prey in the same manner as the true kestrels, have left it with similar physical characteristics and hunting methods. The entire genus are all so closely related that most or all can be hybridized by artificial insemination.
3D Realms was eventually acquired in part by Interceptor Entertainment, and in 2014, Interceptor announced plans to make a new Duke Nukem game, Duke Nukem: Mass Destruction. Gearbox filed suit against 3D Realms and Interceptor based on the fact that Gearbox now owned the rights to the Duke Nukem franchise. The case was settled out of court in August 2015, with 3D Realms and Interceptor acknowledging that Gearbox has full rights to the Duke Nukem series. Following the settlement, Gearbox released Duke Nukem 3D: 20th Anniversary Edition World Tour in September 2016. The game included new levels developed in conjunction with some of the original developers, re-recorded lines by original Duke voice actor Jon St. John, and new music from original composer Lee Jackson. It was released on October 11, 2016.
Sources: en.wikipedia.org
== Chart performance == "Magic" charted most successfully in Canada, where it topped the RPM national singles chart on 19 July 1975, and received a gold certification. It climbed as far as number 11 on the UK Singles Chart and reached number 5 during the summer of 1975 in the US on the Billboard Hot 100.
In critical illness, inflammation increases tanycyte D2 in the paraventricular nucleus (PVN) of the hypothalamus, leading to local tissue hyperthyroidism. There may also be decreased central D3. This causes negative feedback on the HPT axis, and therefore reduced TRH gene expression in the PVN. This is exemplified by the common NTIS phenotype of low TSH even in the face of peripheral hypothyroidism.
Some non-α-amino acids exist in organisms. In these structures, the amine group is displaced further from the carboxylic acid end of the amino acid molecule. Thus a β-amino acid has the amine group bonded to the second carbon away, and a γ-amino acid has it on the third. Examples include β-alanine, GABA, and δ-aminolevulinic acid.
In 1877, the colonial authorities created the Quthing District and appointed Hamilton Hope as the magistrate to oversee the Baputhi, a move opposed by Moorosi. In April 1878, the colonial authorities dispatched 80 African policemen and 700 Basuto warriors to apprehend Moorosi's son Tota; the dispute was resolved peacefully. Hope was replaced by the more experienced John Austen, who was likewise distrusted by Moorosi. Tota was finally imprisoned after being implicated in horse theft, his subsequent escape from captivity and Moorosi's refusal to hand him over impelled Cape Colony prime minister Sir Gordon Sprigg to authorize the forced disarmament of the Baphuthi. Austen ordered Letsie I to assist the Cape in the campaign, threatening to hand over parts of Quthing to white settlers and establish garrisons of colonial troops in Basutoland. Letsie I reluctantly agreed. The fighting lasted for several months, as the Baphuthi had entrenched themselves in the isolated Mount Moorosi. On 28 November 1879, the colonial troops managed to reach the summit with ladders, killing Moorosi in the final confrontation. Moorosi's severed head was paraded in King William's Town, an act that shocked Letsie I.
In 1970, lithium was approved by the United States Food and Drug Administration for the treatment of bipolar disorder, which remains its primary use in the United States. It is sometimes used when other treatments are not effective in a number of other conditions, including major depression, schizophrenia, disorders of impulse control, and some psychiatric disorders in children. Because the FDA has not approved lithium for the treatment of other disorders, such use is off-label. Lithium is unique among medications in that it is proven to prevent suicide in mood disorders such as bipolar disorder and recurrent major depression. The mechanisms of biological action of lithium are only partially understood. For instance, studies of lithium-treated patients with bipolar disorder show that, among many other effects, lithium partially reverses telomere shortening in these patients and also increases mitochondrial function, although how lithium produces these pharmacological effects is not understood. High blood levels of lithium can lead to lithium toxicity.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.